Skip to main content

Table 1 Basic characteristics of study groups

From: The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus

Characteristic Co CoCin DiabCo DiabCin Pdiabetes Ptreatment Pinteraction
Blood glucose (mmol/l) 5.8 ± 0.1 6.2 ± 0.1 30.8 ± 0.5* 29.3 ± 1.4* <0.001 0.460 0.209
Water intake (ml/gBW/day) 0.078 ± 0.002 0.090 ± 0.002 0.787 ± 0.006* 0.597 ± 0.013* <0.001 <0.001 <0.001
Heart weight (g) 1.20 ± 0.06 1.24 ± 0.07 0.91 ± 0.04* 0.84 ± 0.03* <0.001 0.805 0.278
Body weight (g) 480.7 ± 17.6 477.8 ± 20.9 293.5 ± 11.1* 247.6 ± 14.8* <0.001 0.150 0.202
Heart weight/body weight 0.249 ± 0.008 0.259 ± 0.008 0.311 ± 0.009* 0.348 ± 0.015* <0.001 0.026 0.196
  1. The values of blood glucose, daily water intake, heart weight, body weight (BW) and heart weight to body weight ratio are shown of the study groups—vehicle-treated controls (Co), cinaciguat-treated controls (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated diabetic (DiabCin) groups. Values are mean ± SEM of 10–12 experiments per group
  2. * P < 0.05 vs. Co
  3. P < 0.05 vs. DiabCo (Tukey HSD test)